Alzamend Neuro is expected to report a consensus EPS of -$0.56 on zero revenue for the quarter ending July 31, 2026, as the stock currently trades at $1.67, significantly below the average analyst price target of $26.00. Investors are primarily focused on the clinical trajectory of AL001, specifically seeking topline data updates from the Phase II "Lithium in Brain" study for Bipolar Disorder and Alzheimer’s disease.
Recent data from the company's healthy subject trials demonstrated that AL001 achieves bioequivalence and superior brain penetration compared to standard lithium carbonate. This progress is critical as management pursues the FDA’s 505(b)(2) regulatory pathway to address major neurodegenerative and psychiatric conditions while managing its current cash runway.